Artivion (NYSE:AORT) (NYSE: AORT) is a global medical device company specializing in the development, manufacturing and marketing of advanced surgical technologies for the treatment of cardiovascular and vascular diseases. The company’s core offerings include biologic implants, synthetic grafts and surgical sealants designed to improve patient outcomes in complex cardiac and vascular procedures. Artivion’s product portfolio addresses a broad range of clinical needs such as aortic aneurysm repair, structural heart disease and peripheral vascular reconstruction.
Artivion’s biologic implant line leverages proprietary tissue processing techniques to create decellularized vascular and soft tissue grafts that offer enhanced biocompatibility and long-term durability. Its synthetic graft products feature woven and knitted materials engineered for high burst strength and flexibility, while its sealant solutions provide hemostatic support to reduce bleeding and postoperative complications. The company continuously invests in research and development to advance its next-generation portfolio, focusing on minimally invasive delivery methods and regenerative medicine approaches.
Founded in Birmingham, Alabama, in 1965, Artivion has grown both organically and through strategic acquisitions to establish a presence in more than 50 countries. The company operates manufacturing and distribution facilities across North America, Europe and Asia, with a sales and clinical support organization dedicated to collaborating with hospitals, surgeons and academic institutions worldwide. Artivion’s global footprint enables it to address the unique regulatory and clinical requirements of diverse markets.
Artivion’s leadership team is headed by President and Chief Executive Officer Frank J. Madden Jr., whose background in medical technology and private equity has guided the company through significant transformation and growth. Under his direction, Artivion has sharpened its strategic focus on innovative product development, streamlined operations and expanded commercial capabilities. The company remains committed to partnering with healthcare professionals to advance surgical care and improve patient quality of life.
